Abstract
The density of tumor antigen in conjunction with major histocompatibility complex (MHC) class I molecules on the cell surface affects cytotoxic T cell (CTL) function in an active antitumor immune response. Thus, methods to enhance antigen expression/presentation could augment the effect of cancer immune therapy. In the present study, we investigated the feasibility of modifying a cytokine signal peptide with a tumor antigenic epitope. We inserted the genes encoding the MHC class I-restricted antigenic epitope of chicken ovalbumin and tyrosinase-related protein 2 into the signal sequence of the interleukin-2 gene, replacing part of the signal sequence at different positions. Our results showed that these modified signal peptides still functioned, as indicated by cytokine secretion. The antigenic epitope within the modified signal peptide could be processed properly and presented on tumor cell surface. Tumor cells demonstrated enhanced immunogenicity as indicated by increased susceptibility to CTL lysis in vitro and decreased tumor grow in vivo after gene modification. These data provide potential perspectives in designing therapeutic or vaccine strategies in immuno-gene therapy of cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lefebvre S, Moreau P, Dausset J, Carosella ED, Paul P . Downregulation of HLA class I gene transcription in choriocarcinoma cells is controlled by the proximal promoter element and can be reversed by CIITA. Placenta. 1999;20:293–301.
Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C . Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res. 2001;61:1095–1099.
McAdam AJ, Felcher A, Woods ML, et al. Transfection of transforming growth factor-beta producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytes. J Immunother Emphasis Tumor Immunol. 1994;15:155–164.
Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328–332.
Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A . Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer. 1996;66:470–476.
Lehmann F, Marchand M, Hainaut P, et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol. 1995;25:340–347.
Gilmore R, Blobel G, Walter P . Protein translocation across the endoplasmic reticulum. I. Detection in the microsomal membrane of a receptor for the signal recognition particle. J Cell Biol. 1982;95:463–469.
Walter P, Johnson AE . Signal sequence recognition and protein targeting to the endoplasmic reticulum membrane. Annu Rev Cell Biol. 1994;10:87–119.
Henderson RA, Michel H, Sakaguchi K, et al. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science. 1992;255:1264–1266.
Uger RA, Barber BH . Presentation of an influenza nucleoprotein epitope incorporated into the H-2Db signal sequence requires the transporter-associated with antigen presentation. J Immunol. 1997;158:685–692.
Khanna R, Burrows SR, Argaet V, Moss DJ . Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. Int Immunol. 1994;6:639–645.
Sherritt M, Cooper L, Moss DJ, Kienzle N, Altman J, Khanna R . Immunization with tumor-associated epitopes fused to an endoplasmic reticulum translocation signal sequence affords protection against tumors with down-regulated expression of MHC and peptide transporters. Int Immunol. 2001;13:265–271.
von Heijne G . The signal peptide. J Membr Biol. 1990;115:195–201.
Rotzschke O, Falk K, Stevanovic S, Jung G, Walden P, Rammensee HG . Exact prediction of a natural T cell epitope. Eur J Immunol. 1991;21:2891–2894.
Harada M, Tamada K, Abe K, et al. Characterization of B16 melanoma-specific cytotoxic T lymphocytes. Cancer Immunol Immunother. 1998;47:198–204.
Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA, Kawakami Y . Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 1998;58:4895–4901.
Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR . T cell receptor antagonist peptides induce positive selection. Cell. 1994;76:17–27.
Moore MW, Carbone FR, Bevan MJ . Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell. 1988;54:777–785.
Geiser M, Cebe R, Drewello D, Schmitz R . Integration of PCR fragments at any specific site within cloning vectors without the use of restriction enzymes and DNA ligase. Biotechniques. 2001;31:88–90, 92.
Gillis S, Smith KA . Long term culture of tumour-specific cytotoxic T cells. Nature. 1977;268:154–156.
Sladowski D, Steer SJ, Clothier RH, Balls M . An improved MTT assay. J Immunol Methods. 1993;157:203–207.
Karttunen J, Shastri N . Measurement of ligand-induced activation in single viable T cells using the lacZ reporter gene. Proc Natl Acad Sci USA. 1991;88:3972–3976.
Bednarek AK, Keck-Waggoner CL, Daniel RL, et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res. 2001;61:8068–8073.
Barth Jr RJ, Mule JJ, Spiess PJ, Rosenberg SA . Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med. 1991;173:647–658.
Paillard F . Immuno-gene therapy for myeloma using cytokines. Hum Gene Ther. 1998;9:1–2.
Heinzerling LM, Feige K, Rieder S, et al. Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. J Mol Med. 2001;78:692–702.
Blobel G, Dobberstein B . Transfer of proteins across membranes. I. Presence of proteolytically processed and unprocessed nascent immunoglobulin light chains on membrane-bound ribosomes of murine myeloma. J Cell Biol. 1975;67:835–851.
Blobel G, Dobberstein B . Transfer to proteins across membranes. II. Reconstitution of functional rough microsomes from heterologous components. J Cell Biol. 1975;67:852–862.
Kaiser CA, Preuss D, Grisafi P, Botstein D . Many random sequences functionally replace the secretion signal sequence of yeast invertase. Science. 1987;235:312–317.
Gallimore A, Schwarz K, van den BM, Hengartner H, Groettrup M . The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leader-derived T cell epitope. Mol Immunol. 1998;35:581–591.
Bai A, Forman J . The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules. J Immunol. 1997;159:2139–2146.
Yewdell JW, Snyder HL, Bacik I, et al. TAP-independent delivery of antigenic peptides to the endoplasmic reticulum: therapeutic potential and insights into TAP-dependent antigen processing. J Immunother. 1998;21:127–131.
Guilloux Y, Bai XF, Liu X, Zheng P, Liu Y . Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells. Cancer Res. 2001;61:1107–1012.
Qin Z, Harders C, Cao X, Huber C, Blankenstein T, Seliger B . Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors. Cancer Res. 2002;62:2856–2860.
Valitutti S, Muller S, Dessing M, Lanzavecchia A . Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med. 1996;183:1917–1921.
Tso CL, Zisman A, Pantuck A, et al. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res. 2001;61:7925–7933.
Acknowledgements
We thank Debbie Sakiestewa and Domonic Titone for their excellent technical support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
He, X., Tsang, T., Luo, P. et al. Enhanced tumor immunogenicity through coupling cytokine expression with antigen presentation. Cancer Gene Ther 10, 669–677 (2003). https://doi.org/10.1038/sj.cgt.7700618
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700618
Keywords
This article is cited by
-
Immuno-gene therapy of melanoma by tumor antigen epitope modified IFN-γ
Cancer Immunology, Immunotherapy (2005)